Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 99-108

  Dierkes, Jutta ^a   Luley, Claus ^a   Westphal, Sabine ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Cardiovascular disease; Diuretics; Fibrates; Homocysteine

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CIPROFIBRATE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL SUCCINATE; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; SIMVASTATIN;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG MEGADOSE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTRIGLYCERIDEMIA; MONOTHERAPY; NONHUMAN; REVIEW; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 34249891934     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Altschul R, Hoffer A, Stephen JD. 1955. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys, 54:558-9.
2. Assmann G, Schulte H, Funke H, et al. 1998. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J, 19(Suppl M):M8-14
3. Atar I, Korkmaz ME, Demircan S, et al. 2005. Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis, 181:399-402.
4. Basu TK, Mann S. 1997. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic: effects. J Nutr, 127:117-21.
5. Bissonnette R, Treacy E, Rozen R, et al. 2001. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis, 155:455-62
6. Böger R.H, Lentz SF, Bode-Böger SM, et al. 2001. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond), 100:161-7
7. Bourque C, St-Onge MP, Papamandjaris AA, et al. 2003. Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women. Metabolism, 2003: 52:771-7.
8. Boushey CJ, Beresford SA, Omenn GS, et al. 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 274:1049-57.
9. Broeders N, Knoop C, Antoine M, et al. 2000. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant, 15:1993-9.
10. Brown WV. 1987. Potential use of fenofibrate and fibric acid derivatives in the clinic. Am J Med, 83:85-9
11. Cabrini L, Bochicchio D, Bordoni A, et al. 2005. Correlation between dietary polyunsaturated fatty acids and plasma homocysteine concentration in vitamin 136-deficient rats. Nutr Metab Cardiovasc Dis, 15:94-9.
12. Celermajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340:1111-15.
13. Chambers JC, Obeid OA, Kooner JS. 1999. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol, 19:2922-7.
14. Clarke R. 2005. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med, 5:215-22
15. Cleophas TJ, Hornstra N, van Hoogstraten B, et al. 2000. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol, 86:1005-9, A8.
16. de Lorgeril M, Salen P, Paillard F, et al. 1999. Lipid-lowering drugs and homocysteine. Lancet, 353:209-10
17. Dierkes J, Jeckel A, Ambrosch A, et al. 2001. Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. Metabolism, 50:640-645
18. Dierkes J, Westphal S, Kunstmann S, et al. 2001. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis, 158:161-4.
19. Dierkes J, Westphal S, Luley C: 1999. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet, 354:219-20.
20. Ford ES, Smith SJ, Stroup DF, et al. 2002. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol, 31:59-70.
21. Freis ED. 1995. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med, 122:223-6.
22. Fruchart JC, Duriez P. 2002. HDL and triglyceride as therapeutic targets. Curr Opin Lipidol, 13:605-16.
23. Fruchart JC, Staels B, Duriez P. 2001. The role of fibric acids in atherosclerosis. Curr Atherosclerosis Rep, 3:83-92.
24. Garg R, Malinow M, Pettinger M, et al. 1999. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J, 138:1082-7.
25. Genest J, Frohlich J, Steiner G. 2004. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol, 93:848-53.
26. Giral P, Bruckert E, Jacob N, et al. 2001. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis, 154:421-7.
27. Gotto AM Jr. 2005. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol, 96(5A):34F-8F.
28. Grundt H, Nilsen DW, Hetland O, 1999. Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Thromb Haemost, 81:561-5.
29. Grundt H, Nilsen DW, Mansoor MA, et al. 2003. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol Haemost Thromb, 33:88-95.
30. Harats D, Yodfat O, Doolman R, et al. 2001. Homocysteine elevation with fibrates: is it a class effect? Isr Med Assoc J, 3:243-6.
31. Homocysteine Lowering Trialists' Collaboration. 2005. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr, 82:806-12.
32. Homocysteine Lowering Trialists' Collaboration. 1998. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ, 316:894-8
33. Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 288:2015-22.
34. Hottelart C, el Esper N, Achard JM, et al. 1999. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency [French) Nephrologie, 20:41-4.
35. Hottelart C, El Esper N, Rose F, et al. 2002. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron, 92:36-41.
36. Jacques PF, Bostom AG, Wilson PW, et al. 2001. Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr, 73:13-621.
37. Jeppesen J, Hein HO, Suadicani, P, et al. 1998. Triglyceride concentration and ischemic heart disease: an eight-year follow up in the Copenhagen Male Study. Circulation, 97:1029-1036.
38. Jonkers IJAM, de Man FHAF, Onkenhout W, et al. 1999. Implications of fibrate therapy for homocysteine. Lancet, 354:1208.
39. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 366:1849-61.
40. Kelly PJ, Rosand J, Kistler JP, et al. 2002. Homocysteine, MTHFR 677C--> T polymorphism, and risk of ischemic stroke: results ofa meta-analysis. Neurology, 59:529-36.
41. Kezdi P, Kezdi PC, Khamis HJ. 1992. Diuretic induced long term hemodynamic changes in hypertension. A retrospective study in a MRFIT clinical center. Clin Exp Hypertens, A14:347-65.
42. Khan KNM, et al. 2002. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int, 61:1210-19.
43. Knopp RH. 1999. Drug treatment of lipid disorders. N Engl J Med, 341:498-511.
44. Korkmaz ME, Atar I, Tayfun E, et al. 2003 Effects of a beta-blocker and spironolactone on plasma homocysteine levels. Int J Cardiol, 88:119-20
45. Landray MJ, Townend JN, Martin S, et al. 1999. Lipid-lowering drugs and homocysteine. Lancet, 353:1974-1975.
46. Lange H, Suryapranata H, De Luca G, et al. 2004. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med, 350:2673-81.
47. Legendre C, Causse E, Chaput E, et al 2002. Fenofibrate induces a selective increase ofprotein-bound homocysteine in rodents: a PPARalpha-mediated effect. Biochem Biophys Res Commun, 295:1052-6.
48. Li H, Lewis A, Brodsky S, et al. 2002. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation, 105:1037-43.
49. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. 2003. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol, 41:2105-13.
50. Lipscombe J, Bargman JM. 2001. Fibrate-induced increase in blood urea and creatinine. Nephrol Dial Transplant, 16:1515.
51. Luc G, Jacob N, Bouly M, et al. 2004. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol, 43:452-3.
52. MacMahon M, Kirkpatrick C, Cummings CE, et al. 2000. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis, 10:195-203.
53. Mayer Jr O, Simon J, Holubec L, et al. 2005. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. Physiol Res, 2005 Dec 12; [Epub ahead of print].
54. Mayer O Jr, Simon J, Holubec L, et al. 2003. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol, 59:367-71.
55. Melenovsky V, Stulc T, Kozich V, et al. 2003. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. Am Heart J, 146:110.
56. Melenovsky V, Malik J, Wichterle D, et al. 2002. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J, 144:E6.
57. Milionis HJ, Papakostas J, Kakafika A, et al. 2003. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol, 43:825-30.
58. Moller J, Nielsen GM, Tvedegaard KC, et al. 2000. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest, 60:491-9.
59. Montenero AS. 1980. Drugs producing vitamin deficiencies. Acta Vitaminol Enzymol, 2:27-45.
60. Morrow LE, Grimsley EW. 1999. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. South Med J, 92:866-70.
61. Mudd SH, Poole JR. 1975. Labile methyl balances for normal humans on various dietary regimens. Metabolism, 24:721-735.
62. Nappo F, De Rosa N, Marfella R, et al. 1999. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA, 281:2113-18.
63. Nygard O, Nordrehaug JE, 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med, 337:230-6.
64. Nygard O, Vollset SE, Refsum H, et al. 1995. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA, 274:1526-33.
65. Olszewski AJ, McCully KS. 1993. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis, 4:53-60.
66. Parhofer KG. 2005. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. Exp Clin Endocrinol Diabetes, 113:414-17.
67. Piolot A, Blache D, Boulet L, et al. 2003. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med, 141:41-9.
68. Ridker PM, Shih J, Cook TJ, et al. 2002. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation, 105:1776-9.
69. Schnyder G, Roffi M, Pin R, et al. 2001. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med, 345:1593-1600.
70. Sebestjen M, Keber I, Zegura B, et al. 2004. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost, 92:1129-35.
71. Sharabi Y, Doolman R, Rosenthal T, et al. 1999. Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens, 12:766-71.
72. Sutton-Tyrrell K, Bostom A, Selhub J, et al. 1997. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation, 16:1745-9.
73. Stulc T, Melenovsky V, Grauova B, et al. 2001. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition, 17:721-3.
74. Stulc T, Kasalova Z, Krejci H, et al. 2005. Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis, 183:367-8.
75. Syvanne M, Whittall RA, Turpeinen U, 2004. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis, 172:267-72.
76. Tawakol A, Omland T, Gerhard M, et al. 1997. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation, 95:1119-21.
77. Thambyrajah J, Landray MJ, Jones HJ, et al. 2001. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol, 37:1858-63.
78. Thambyrajah J, Townend JN. 2000. Homocysteine and atherothrombosis - mechanisms for injury. Eur Heart J, 21:967-74.
79. THE BIP STUDY GROUP. 2000. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 102:21-7.
80. The Diabetes Atherosclerosis Intervention Study Investigators. 2001. Effect of fenofibrate on progression ofcoronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 24; 357:905-10.
81. Toole JF, Malinow MR, Chambless LE, et al. 2004. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 291:565-75.
82. van Guldener C, Nanayakkara PW, Stehouwer CD. 2003. Homocysteine and blood pressure. Curr Hypertens Rep, 5:26-31.
83. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325:1202.
84. Wang W, Basinger A, Neese RA, et al. 2001. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab, 280:E540-547.
85. Welch GN, Loscalzo J. 1998. Homocysteine and atherothrombosis. N Engl J Med, 338:1042-50.
86. Westphal S, Dierkes J, Luley C. 2001. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet, 358:39-40.
87. Westphal S, Rading A, Luley C, Dierkes J. 2003. Antihypertensive treatment and homocysteine concentrations. Metabolism, 52:261-3. Wilson KM, Lentz SR. 2005. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med, 5:163-71.
88. Wilson MW, Lay LT, Chow CK, et al. 1995. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch Toxicol, 69:491-7.
89. Yoshinari M, Asano T, Kaori S, et al. 1998. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Diabetes Res Clin Pract, 42:149-54.
90. Zeman M, Zak A, Vecka M, et al. 2006. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr Biochem, 17:379-84.
91. Zhao XQ Morse JS, Dowdy AA, et al. 2004. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol, 93:307-12.